ArticleCytotechnology2001
Development and improvement of a serum-free suspension process for the production of recombinant adenoviral vectors using HEK293 cells.
Article in Cytotechnology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Multi-omics reveal molecular changes during suspension adaptation of HEK293 cells.Applied microbiology and biotechnology · 2026Article
- A strategic approach to multi-omics literature retrieval in next generation mammalian cell bioprocessing.NPJ systems biology and applications · 2025Review
- Reduced aggregation of the leghorn male hepatoma cell line in suspension by supplementing dextran sulfate in the media.Animal bioscience · 2025Article
- Adenoviral-Vectored Centralized Consensus Hemagglutinin Vaccine Provides Broad Protection against H2 Influenza a Virus.Vaccines · 2022Article
- Mammalian Cell Culture as a Platform for Veterinary Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Perspectives on scaling production of adipose tissue for food applications.Biomaterials · 2022Article
- Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.Human gene therapy · 2021Article
- Mucin-coating technologies for protection and reduced aggregation of cellular production systems.Biotechnology and bioengineering · 2019Article
- FGF, Insulin, and SMAD Signaling Cooperate for Avian Primordial Germ Cell Self-Renewal.Stem cell reports · 2015Article
- Better and faster: improvements and optimization for mammalian recombinant protein production.Current opinion in structural biology · 2014Review
- Characterization of growth and Oryctes rhinoceros nudivirus production in attached cultures of the DSIR-HA-1179 coleopteran insect cell line.Cytotechnology · 2013Article
- Enhancement of antibody production by the addition of Coenzyme-Q(10).Cytotechnology · 2011Article
- Heparin promotes suspension adaptation process of CHO-TS28 cells by eliminating cell aggregation.Molecular biotechnology · 2011Article
- Production of adenovirus vectors and their use as a delivery system for influenza vaccines.Expert opinion on biological therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Embryonic Kidney 293 (HEK293) cells were adapted into a serum-free suspension medium through steps of gradual serum weaning for the production of adenoviral (AdV) gene therapy vectors. The presence of sodium heparin in the medium formulation reduced cell clumping dramatically in suspension culture. The adapted cells were ready to grow either in serum-containing medium as an attached culture or in serum-free medium in suspension culture. A scalable production process was developed in shake flasks and was then evaluated in stirred tank bioreactors. This process includes a growth phase in batch-mode followed by a production phase involving medium perfusion and supplementation. Fortification with calcium chloride post viral inoculation resulted in an increase in virus production by at least one fold. Addition of stimulating agents such as sodium butyrate, N-acetyl-L-cysteine (NAC), dimethyl sulfoxide(DMSO), or ethyl alcohol post infection was shown to further improve virus production in a dose-dependent manner. The serum-free suspension process described here should be suitable for the manufacturing of other E1-deleted AdV vectors and could potentially be used for the production of recombinant proteins by HEK293 cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.